Published literature

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia

Reparixin improves survival in critically ill and transplant patients: A meta-analysis

The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials

Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis

Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice

Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis

The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome

Clinical Trial Resources*

REPAVID-22 Clinical Trial Brochure REPAVID-22 Clinical Trial Pocket Card REPAVID-22 Clinical Trial Poster RESPIRATIO Clinical Trial Brochure RESPIRATIO Clinical Trial Pocket Card RESPIRATIO Clinical Trial Poster

*These resources are intended for healthcare professionals only and and are in the English language. Please contact the study team for other languages and for patient facing materials at your site.